Literature DB >> 8583218

Neurocysticercosis: optimal dose treatment with albendazole.

I Cruz1, M E Cruz, F Carrasco, J Horton.   

Abstract

Albendazole has been used successfully in the treatment of cerebral cysticercosis for several years. The published dosage schedule has varied from 15 mg/kg/day for 8 days to up to 30 days. Fifty three patients with neurocysticercosis received 8, 15 or 30 days treatment with 800 mg of albendazole daily. The present study demonstrates the effectiveness in clinical and radiological terms of albendazole 800 mg/day for 8 days for the majority of patients affected with cystic or encephalitic parenchymatous cysticercosis. There was no apparent advantage of continuation of treatment for 15 or 30 days in this series. The routine use of high dose steroids limited the effects of parasite destruction. No toxicity attributable to albendazole was encountered.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8583218     DOI: 10.1016/0022-510x(95)00181-z

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

Review 1.  Neurocysticercosis--New Millennium, ancient disease and unending debate.

Authors:  G Narula; K S Bawa
Journal:  Indian J Pediatr       Date:  2003-04       Impact factor: 1.967

2.  Neurocysticercosis.

Authors:  Vincent C Marconi; Hector H Garcia; Joel T Katz
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

Review 3.  Anthelmintics for people with neurocysticercosis.

Authors:  Katharine Abba; Sridharan Ramaratnam; Lakshmi Narasimhan Ranganathan
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

4.  Disseminated cysticercosis.

Authors:  Soo Yong Park; Min Ho Kong; Jung Hee Kim; Kwan Young Song
Journal:  J Korean Neurosurg Soc       Date:  2011-03-31

Review 5.  Anthelmintics. A comparative review of their clinical pharmacology.

Authors:  N de Silva; H Guyatt; D Bundy
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

6.  Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis.

Authors:  Rekha Devi; Ankit Jain; Pooja Hurkat; Sanjay K Jain
Journal:  Pharm Res       Date:  2015-07-22       Impact factor: 4.200

Review 7.  Neurocysticercosis.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  1998-06       Impact factor: 2.401

Review 8.  Management of neurocysticercosis.

Authors:  Terrence Riley; A C White
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 9.  Pharmacokinetic optimisation of the treatment of neurocysticercosis.

Authors:  J Sotelo; H Jung
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 10.  Current consensus guidelines for treatment of neurocysticercosis.

Authors:  Hector H García; Carlton A W Evans; Theodore E Nash; Osvaldo M Takayanagui; A Clinton White; David Botero; Vedantam Rajshekhar; Victor C W Tsang; Peter M Schantz; James C Allan; Ana Flisser; Dolores Correa; Elsa Sarti; Jon S Friedland; S Manuel Martinez; Armando E Gonzalez; Robert H Gilman; Oscar H Del Brutto
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.